Clinical Trial Update: Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating zanubrutinib plus lenalidomide as maintenance therapy in Diffuse Large B-Cell Lymphoma and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Navy General Hospital, Beijing | Conditions: Diffuse Large B-cell Lymphoma | Phase 2 | Status: RECRUITING